MG624, an α7-nAChR antagonist, inhibits angiogenesis via the Egr-1/FGF2 pathway
- 922 Downloads
Small cell lung cancer (SCLC) demonstrates a strong etiological association with smoking. Although cigarette smoke is a mixture of about 4,000 compounds, nicotine is the addictive component of cigarette smoke. Several convergent studies have shown that nicotine promotes angiogenesis in lung cancers via the α7-nicotinic acetylcholine receptor (α7-nAChR) on endothelial cells. Therefore, we conjectured that α7-nAChR antagonists may attenuate nicotine-induced angiogenesis and be useful for the treatment of human SCLC. For the first time, our study explores the anti-angiogenic activity of MG624, a small-molecule α7-nAChR antagonist, in several experimental models of angiogenesis. We observed that MG624 potently suppressed the proliferation of primary human microvascular endothelial cells of the lung (HMEC-Ls). Furthermore, MG624 displayed robust anti-angiogenic activity in the Matrigel, rat aortic ring and rat retinal explant assays. The anti-angiogenic activity of MG624 was assessed by two in vivo models, namely the chicken chorioallantoic membrane model and the nude mice model. In both of these experimental models, MG624 inhibited angiogenesis of human SCLC tumors. Most importantly, the administration of MG624 was not associated with any toxic side effects, lethargy or discomfort in the mice. The anti-angiogenic activity of MG624 was mediated via the suppression of nicotine-induced FGF2 levels in HMEC-Ls. MG624 decreased nicotine-induced early growth response gene 1 (Egr-1) levels in HMEC-Ls, and reduced the levels of Egr-1 on the FGF2 promoter. Consequently, this process decreased FGF2 levels and angiogenesis. Our findings suggest that the anti-angiogenic effects of MG624 could be useful in anti-angiogenic therapy of human SCLCs.
KeywordsMG624 α7-nAChR Nicotine Angiogenesis SCLC FGF2
We thank Dr. Srikumar Chellappan and his laboratory for continuous support. We are grateful to Carla Cook, Dr. Travis Salisbury and Dr. Nalini Santanam for their help in the real-time PCR experiments. We also acknowledge Dr. Cattini and Dr. Nilson for providing us the constructs used in this study. This work was supported by the grants Young Clinical Scientist Award (#82115) from the Flight Attendant Medical Association, Miami, FL, Research Starter Grant from the PhRMA Foundation, Washington D.C., ASPET-Astellas Award, NIH-ROI-NIDDK65003 (to RDE). AMD and KCB are recipients of graduate fellowships from the WVSGC.
Conflict of interest
None of the authors have any conflict of interest.
All experiments were performed in the United States of America and they comply with the laws of the USA.
- 2.Blann AD, Ramcharan KS, Stonelake PS, Luesley D, Lip GY (2011) The angiome: a new concept in cancer biology. J Clin Pathol. doi: 10.1136/jcp.2011.088948
- 8.Martinez-Garcia E, Irigoyen M, Gonzalez-Moreno O, Corrales L, Teijeira A, Salvo E, Rouzaut A (2010) Repetitive nicotine exposure leads to a more malignant and metastasis-prone phenotype of SCLC: a molecular insight into the importance of quitting smoking during treatment. Toxicol Sci 116(2):467–476. doi: 10.1093/toxsci/kfq138 PubMedCrossRefGoogle Scholar
- 20.Paleari L, Catassi A, Ciarlo M, Cavalieri Z, Bruzzo C, Servent D, Cesario A, Chessa L, Cilli M, Piccardi F, Granone P, Russo P (2008) Role of alpha7-nicotinic acetylcholine receptor in human non-small cell lung cancer proliferation. Cell Prolif 41(6):936–959. doi: 10.1111/j.1365-2184.2008.00566.x PubMedCrossRefGoogle Scholar
- 23.Grozio A, Paleari L, Catassi A, Servent D, Cilli M, Piccardi F, Paganuzzi M, Cesario A, Granone P, Mourier G, Russo P (2008) Natural agents targeting the alpha7-nicotinic-receptor in NSCLC: a promising prospective in anti-cancer drug development. Int J Cancer 122(8):1911–1915. doi: 10.1002/ijc.23298 PubMedCrossRefGoogle Scholar
- 24.Paleari L, Sessa F, Catassi A, Servent D, Mourier G, Doria-Miglietta G, Ognio E, Cilli M, Dominioni L, Paolucci M, Calcaterra A, Cesario A, Margaritora S, Granone P, Russo P (2009) Inhibition of non-neuronal alpha7-nicotinic receptor reduces tumorigenicity in A549 NSCLC xenografts. Int J Cancer 125(1):199–211. doi: 10.1002/ijc.24299 PubMedCrossRefGoogle Scholar
- 25.Alama A, Bruzzo C, Cavalieri Z, Forlani A, Utkin Y, Casciano I, Romani M (2011) Inhibition of the nicotinic acetylcholine receptors by cobra venom alpha-neurotoxins: is there a perspective in lung cancer treatment? PLoS One 6(6):e20695. doi: 10.1371/journal.pone.0020695
- 26.Gotti C, Balestra B, Moretti M, Rovati GE, Maggi L, Rossoni G, Berti F, Villa L, Pallavicini M, Clementi F (1998) 4-Oxystilbene compounds are selective ligands for neuronal nicotinic alphaBungarotoxin receptors. Br J Pharmacol 124(6):1197–1206. doi: 10.1038/sj.bjp.0701957 PubMedCrossRefGoogle Scholar
- 30.Wu J, Toyohara J, Tanibuchi Y, Fujita Y, Zhang J, Chen H, Matsuo M, Wang RF, Hashimoto K (2010) Pharmacological characterization of [(125)I]CHIBA-1006 binding, a new radioligand for alpha7 nicotinic acetylcholine receptors, to rat brain membranes. Brain Res 1360:130–137. doi: 10.1016/j.brainres.2010.08.095 PubMedCrossRefGoogle Scholar
- 34.Brown KC, Witte TR, Hardman WE, Luo H, Chen YC, Carpenter AB, Lau JK, Dasgupta P (2010) Capsaicin displays anti-proliferative activity against human small cell lung cancer in cell culture and nude mice models via the E2F pathway. PLoS One 5(4):e10243. doi: 10.1371/journal.pone.0010243
- 38.Kinkade R, Dasgupta P, Carie A, Pernazza D, Carless M, Pillai S, Lawrence N, Sebti SM, Chellappan S (2008) A small molecule disruptor of Rb/Raf-1 interaction inhibits cell proliferation, angiogenesis, and growth of human tumor xenografts in nude mice. Cancer Res 68(10):3810–3818. doi: 10.1158/0008-5472.CAN-07-6672 PubMedCrossRefGoogle Scholar
- 40.Banumathi E, Haribalaganesh R, Sheik Pran Babu S, Sirish Kumar N, Sangiliyandi G (2009) High-yielding enzymatic method for isolation and culture of microvascular endothelial cells from bovine retinal blood vessels. Microvasc Res 77(3):377–381. doi: 10.1016/j.mvr.2008.12.005
- 41.Ponce ML, Kleinmann HK (2003) The chick chorioallantoic membrane as an in vivo angiogenesis model. Curr Protoc Cell Biol. Chapter 19:Unit 19 15. doi: 10.1002/0471143030.cb1905s18
- 43.Song P, Sekhon HS, Lu A, Arredondo J, Sauer D, Gravett C, Mark GP, Grando SA, Spindel ER (2007) M3 muscarinic receptor antagonists inhibit small cell lung carcinoma growth and mitogen-activated protein kinase phosphorylation induced by acetylcholine secretion. Cancer Res 67(8):3936–3944PubMedCrossRefGoogle Scholar
- 47.Chang PY, Lu SC, Lee CM, Chen YJ, Dugan TA, Huang WH, Chang SF, Liao WS, Chen CH, Lee YT (2008) Homocysteine inhibits arterial endothelial cell growth through transcriptional downregulation of fibroblast growth factor-2 involving G protein and DNA methylation. Circ Res 102(8):933–941. doi: 10.1161/CIRCRESAHA.108.171082 PubMedCrossRefGoogle Scholar
- 49.Kundumani-Sridharan V, Niu J, Wang D, Van Quyen D, Zhang Q, Singh NK, Subramani J, Karri S, Rao GN (2010) 15(S)-hydroxyeicosatetraenoic acid-induced angiogenesis requires Src-mediated Egr-1-dependent rapid induction of FGF-2 expression. Blood 115(10):2105–2116. doi: 10.1182/blood-2009-09-241802 PubMedCrossRefGoogle Scholar
- 51.Dom AM, Buckley AW, Brown KC, Egleton RD, Marcelo AJ, Proper NA, Weller DE, Shah YH, Lau JK, Dasgupta P (2010) The α7-nicotinic acetylcholine receptor and MMP-2/9 pathway mediate the pro-angiogenic effect of nicotine in human retinal endothelial cells. Invest Ophthalmol Vis Sci. doi: 10.1167/iovs.10-5461
- 53.Cucina A, Corvino V, Sapienza P, Borrelli V, Lucarelli M, Scarpa S, Strom R, Santoro-D’Angelo L, Cavallaro A (1999) Nicotine regulates basic fibroblastic growth factor and transforming growth factor beta1 production in endothelial cells. Biochem Biophys Res Commun 257(2):306–312PubMedCrossRefGoogle Scholar
- 59.Ganti AK, West WW, Lackner RP, Kessinger A (2010) Current concepts in the diagnosis and management of small-cell lung cancer. Oncology (Williston Park) 24(11):1034–1039Google Scholar